Adizem is used across three main therapeutic areas. It is utilized in clinical settings marked by discomfort or symptoms related to conditions involving increased physiological stress.

This medication is generally used for managing elevated blood pressure (Hypertension), addressing Angina Pectoris (chest discomfort), and controlling specific supraventricular rhythm disorders such as Atrial Fibrillation and Atrial Flutter. It helps address symptom clusters that may become intense or disruptive across multiple cardiovascular domains.

---

Easing Discomfort and Managing Episodes of Angina Pectoris

This domain covers the management and managing the occurrence of chest pain or discomfort, particularly that which occurs during physical activity. Adizem contributes to easing the overall symptom load and helps address fluctuating symptoms, thereby providing support that helps ease the overall burden of symptoms and assisting with maintaining functional stability.

“Adizem is applied in situations where additional symptomatic support is needed to help patients cope more steadily with symptom fluctuations in their day-to-day comfort.”

---

Controlling Rapid Heart Rhythms and Palpitation Symptoms

Adizem is applied across domains where additional symptomatic support is needed to manage specific supraventricular rhythm disorders where patients experience rapid, distressing heartbeats. It plays a role in easing the symptoms of heightened physiological activity, which contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Primary Therapeutic Domains
Main Uses	Supportive relief for symptoms of rapid heartbeats; managing the occurrence of chest discomfort; addressing elevated systemic pressure.
Scenario	Episodic or recurrent supraventricular rhythm disturbances and chronic hypertension management.
Benefit	Assists with maintaining functional stability and supports patients during episodes of heightened discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information on Diltiazem

Eligibility Profile: Adizem (Diltiazem)

Adizem is generally indicated for use in adults for the management of high blood pressure or angina. Eligibility is strictly defined by regulatory warnings and contraindications.

Contraindicated (Must Not Use)	Not Recommended/Use with Caution
Hypersensitivity to diltiazem or excipients.	Pediatric Population (safety/efficacy not established).
Severe Hypotension (low blood pressure).	Pregnancy/Women of child-bearing potential.
Severe Bradycardia (very slow heart rate).	Nursing Mothers (excreted in breast milk).
Second- or Third-Degree AV Block (without a pacemaker).	Impaired Hepatic or Renal Function (close monitoring required).
Sick Sinus Syndrome (without a pacemaker).	Reduced Left Ventricular Function or heart failure history.
Decompensated Cardiac Failure or Pulmonary Congestion.	Concurrent use with a beta-blocker (additive effect on heart rhythm/rate).
Concurrent use with dantrolene infusion or lomitapide.	Acute Porphyria (considered unsafe).

Note: Patients with certain severe heart conduction disorders (AV block, sick sinus syndrome) are only eligible if a functioning ventricular pacemaker is present.

Adizem (diltiazem) can interact with many other medicines by two primary mechanisms: additive effects on the heart and effects on drug metabolism.

Cardiovascular Interactions

Because Adizem can slow heart rate and heart conduction, caution is required with other medications that have similar effects, such as beta-blockers and digitalis glycosides (digoxin). The combination may lead to a dangerously slow heart rate or abnormal heart rhythms (AV block). For this reason, some medicines, such as ivabradine, are strictly contraindicated (must not be taken).

Metabolic Interactions

Adizem is a moderate inhibitor of the CYP3A4 enzyme system in the liver, which is responsible for breaking down many drugs. Taking Adizem with drugs that are processed by this enzyme can increase the concentration of the other drug in the bloodstream, raising the risk of side effects. This affects numerous medications, including:

• Certain Statins (e.g., simvastatin): Diltiazem can increase the statin’s level, which may require a dose limit or change to a different cholesterol-lowering medication.
• Immunosuppressants (e.g., ciclosporin, tacrolimus).
• Certain Anxiolytics/Hypnotics (e.g., midazolam, triazolam).
• Certain Anticonvulsants (e.g., carbamazepine).

Conversely, drugs that stimulate (induce) the CYP3A4 enzyme, such as rifampin or the herbal supplement St. John’s Wort, can reduce the level of Adizem, making it less effective. Consult with a healthcare professional before combining Adizem with any other medication, supplement, or herbal product.

Adizem, whose active substance is diltiazem, functions as a non-dihydropyridine calcium channel blocker. Its primary biological targets are the voltage-gated L-type calcium channels ( Ca V1.2), which are abundant in cardiac muscle cells (myocardium) and vascular smooth muscle tissue. The drug acts as an inhibitor, binding to the central cavity of the channel's alpha-1 subunit and physically impeding the influx of extracellular calcium ions during membrane depolarization.

In vascular smooth muscle, this inhibition of calcium ion entry limits the activation of the myosin light chain kinase ( MLCK) pathway, preventing the phosphorylation of myosin light chains. The intracellular consequence is a reduction in myofilament interaction and subsequent smooth muscle relaxation, resulting in vasodilation and a systemic decrease in vascular resistance. In cardiac tissue, the blockade reduces the availability of calcium for excitation-contraction coupling, yielding a negative inotropic effect (decreased contractility). Furthermore, the inhibition of calcium influx in the sinoatrial (SA) and atrioventricular (AV) nodal tissues modifies the action potential, decreasing the rate of spontaneous depolarization and slowing impulse conduction, respectively. The system-level physiological consequences include modulation of cardiac chronotropy and dromotropy, coupled with peripheral and coronary vasodilation.

Official Administration Guidelines

Adizem (diltiazem hydrochloride) is administered via oral (tablet or extended-release capsule) or intravenous (IV) routes, following established clinical protocols.

---

Oral Dosing and Preparation

Formulation Type	Frequency and Dosing	Preparation Requirement
Extended-Release (e.g., Angina)	Initial dose typically 120 mg to 180 mg once daily. The dosage is adjusted (titrated) over 7 to 14 days based on clinical response, up to a maximum of 540 mg once daily.	Swallow the tablet or capsule whole; do not chew or crush. Some extended-release capsules may be opened and the contents sprinkled onto a spoonful of applesauce, which must be swallowed immediately without chewing.
Immediate-Release	Typically initiated at 30 mg four times daily (before meals and at bedtime), with gradual dose increases.	Tablets may be swallowed whole, crushed, or chewed, but the 30 mg tablet should not be split.

Intravenous (IV) Administration

The IV route is used for temporary control of rapid heart rate. Administration must occur in a setting with continuous ECG monitoring and frequent blood pressure measurement.

• Initial Bolus Dose: 0.25 mg/kg actual body weight, administered over 2 minutes. If the response is inadequate after 15 minutes, a second dose of 0.35 mg/kg may be given over 2 minutes.
• Continuous Infusion: An infusion is started immediately following the first bolus. The recommended initial rate is typically 5 mg/hour to 10 mg/hour, which may be adjusted in 5 mg/hour increments up to a maximum of 15 mg/hour. Infusion duration should not exceed 24 hours.

Procedural Rules

• Missed Dose: If a dose is missed, take it as soon as possible. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Do not double doses.
• Age-Specific Use: The safety and efficacy for use in children have not been established; administration and dosage for pediatric patients must be determined by a healthcare professional.

---

Research Evidence / Overview of Studies for Adizem

This overview describes the types of research and general findings for Diltiazem (the active ingredient in Adizem) as evaluated in official clinical studies, focusing on what is known and what remains an area of active research. The information below is strictly descriptive of the evidence and is not intended as medical advice or clinical guidance.

---

Research Evidence for Managing High Blood Pressure (Essential Hypertension)

Research examining the use of Diltiazem for high blood pressure primarily involves Randomized Controlled Trials (RCTs). These studies included adults diagnosed with mild to moderate high blood pressure, and they often included comparisons against an inactive substance (placebo) or other active agents.

Researchers examined outcomes related to systemic or functional imbalance, such as the measured changes in systolic and diastolic blood pressure over defined treatment periods. These studies monitored how blood pressure measurements evolved over time. Findings describe patterns observed in the studies, where the blood pressure measurements from baseline were documented.

---

Evidence for Managing Chronic Stable Angina Pectoris

The research for chronic stable angina—chest discomfort often triggered by exertion—has primarily utilized short-term, double-blind, placebo-controlled trials. These studies focused on adults who experienced predictable, effort-related chest discomfort.

Research explored outcomes related to outcomes reflecting daily functioning or activity level, particularly by measuring the duration of exercise tolerance before patients experienced discomfort or specific changes on an ECG. Studies also monitored patient-reported outcomes describing perceived discomfort, such as the frequency of angina episodes. The findings help contextualize how patients reported their experience, with studies reporting observed patterns in which participants in the Diltiazem groups documented longer periods of physical activity and reported fewer episodes of chest discomfort.

---

Studies on Controlling Rapid Heart Rhythms (Atrial Fibrillation/Flutter)

Research concerning the control of rapid heart rhythms in conditions like Atrial Fibrillation or Atrial Flutter generally involved short-term RCTs, particularly for the intravenous (IV) formulation used in acute care settings. These trials typically included adults with rapid heart rates due to the rhythm disorder.

Studies focused on outcomes describing episodic or acute changes, specifically by monitoring the time required to achieve a target heart rate and the magnitude of heart rate change over the initial hours. Studies observed that heart rates rapidly changed following the administration of the IV form. While research describes the observed patterns of heart rate control in acute episodes, the data on the conversion of the rhythm disorder back to a normal rhythm were often secondary.

---

Current Evidence Gaps and Areas of Uncertainty

Follow-up durations were limited in many of the key functional trials, providing insufficient insight into effects that might only appear after many months or years. The research base supporting Diltiazem's primary uses primarily includes short-term and intermediate-term trials lasting a few weeks to a few months. This means that the long-term effects are not fully established regarding the medicine's durability and its direct relationship to reducing major life-threatening cardiovascular events over the course of a lifetime. Comparative evidence is lacking for certain head-to-head comparisons against newer agents or specialized populations, and data for certain groups remain insufficient.

Key Studies & References

1. Diltiazem. NIH Bookshelves, StatPearls [Review of Diltiazem Clinical Evidence]
2. Diltiazem Medication Guide: Uses and Administration. MedlinePlus, National Library of Medicine
3. Management of Atrial Fibrillation: Clinical Guidelines and Evidence Review

Common questions about Adizem (FAQ)

Q: Is Adizem used for blood pressure or heart rhythm?

A: Official regulatory documentation indicates that Adizem is approved for multiple uses concerning the cardiovascular system. These include the treatment of high blood pressure (hypertension) and the management of chronic stable angina (chest pain). It is also approved for controlling certain specific rapid heart rhythms.

Q: Do I need to avoid any specific foods when on Adizem?

A: Official patient warnings advise that the consumption of grapefruit or grapefruit juice should be limited or avoided. This guidance is in place because official information suggests grapefruit may increase the drug's exposure in the bloodstream, potentially leading to increased side effects.

Q: Why is grapefruit juice mentioned in relation to Adizem?

A: Official documents state that grapefruit juice can increase the amount of Adizem that is absorbed into the bloodstream. This occurs because grapefruit can interfere with the way the body typically processes the medication. The resulting increased exposure may heighten the possibility of side effects.

Q: What are the restrictions on who can use Adizem?

A: The official eligibility profile lists several conditions that prohibit use (contraindications). These conditions include severe low blood pressure or certain severe heart rhythm disorders (e.g., second- or third-degree heart block), unless the individual has a functioning pacemaker. Official guidance also advises using the medication with caution in the elderly and in individuals with kidney or liver impairment.

Q: Can I take Adizem if I have kidney issues?

A: Official guidance recommends using Adizem with caution in patients who have impaired renal function (kidney issues). This caution is due to the potential for increased drug levels in the body. Official guidance indicates that periodic monitoring of kidney function may be recommended during treatment.

Q: Can I take Adizem if I have liver issues?

A: Official guidance recommends using Adizem with caution in patients with impaired hepatic function (liver issues). This is because the drug is processed in the liver. Safety documentation indicates that liver function tests may be monitored at regular intervals during prolonged use.

Q: Why do official documents advise caution when using Adizem with certain heart medications?

A: Official documents advise caution because combining Adizem with certain other heart medications, such as beta-blockers, can result in additive depressant effects on the heart. This may increase the risk of specific cardiovascular effects, such as a slow heart rate (bradycardia), low blood pressure (hypotension), or issues with the heart's electrical conduction.

Q: How quickly should I feel a difference after starting Adizem?

A: Official pharmacokinetic data indicates that for the extended-release form, measurable levels of the drug typically appear in the blood within approximately two hours and reach peak concentrations around 10 to 14 hours after taking the medicine. The question of what an individual may feel should be discussed with a healthcare professional.

Q: Can Adizem cause weight gain?

A: Regulatory safety documents list peripheral edema (swelling of the extremities, such as the ankles or feet) as a common adverse reaction. The official adverse reaction listing for the drug includes peripheral edema, which is associated with fluid retention.

Q: How long does Adizem stay in your system?

A: According to official pharmacokinetics data, the plasma elimination half-life for immediate-release formulations is approximately 3.0 to 4.5 hours. For certain extended-release formulations, the half-life is longer, reported as approximately 5 to 8 hours.

Q: Are there different types of Adizem, like slow-release or immediate?

A: Yes, official administrative documents confirm Adizem is available in both immediate-release tablets and various extended-release capsules. The extended-release forms are specifically designed to release the active substance over a prolonged period, such as up to 24 hours.

Q: Can Adizem affect your sleep?

A: Official safety documents report that insomnia (difficulty falling asleep or staying asleep) is listed as an uncommon adverse reaction associated with the medication. This typically affects less than 1% of users.

Q: Why do some people take Adizem for conditions other than high blood pressure?

A: Adizem is approved for multiple distinct uses, not just high blood pressure (hypertension). Official indications include the management of chronic stable angina (chest pain) and the control of specific rapid heart rhythms, making it useful for several cardiovascular issues.

Q: What does official research say about Adizem for its approved uses?

A: Official research studies have examined the drug’s effects on blood pressure reduction, improvement in exercise tolerance in patients with angina, and the control of rapid heart rates. The results from these studies describe the drug’s effects on blood pressure, exercise tolerance, and heart rate, which collectively provide the factual basis for its official regulatory approvals.

Q: What happens if I stop taking Adizem suddenly?

A: Official patient advice recommends patients should avoid abrupt discontinuation of the medicine. Official patient information indicates that the decision to stop treatment should be made in consultation with a healthcare professional.

Q: How long does it take for Adizem to reach its full effect?

A: Clinical studies often measure the maximum benefits, such as the improvement in exercise tolerance for angina, at the time of lowest drug concentration (the trough). This indicates that for full benefits to be assessed, the medication must typically reach stable, steady-state concentrations through consistent use.

Q: Is Adizem approved for use in children?

A: Official regulatory documents confirm that the safety and effectiveness of Adizem for use in the pediatric population (children) has not been established through official studies. The official documentation states the drug’s use in children has not been established.

Q: Does taking Adizem mean I can stop lifestyle changes?

A: Official guidance on managing cardiovascular conditions, such as high blood pressure and angina, typically suggests that medication should be used as part of a comprehensive strategy. Official guidance often includes lifestyle adjustments, such as diet and exercise, as elements intended to complement the medicine’s therapeutic effects.

Q: Is Adizem safe for women who might become pregnant?

A: Official warnings state that the drug is only recommended for use during pregnancy when the treating physician judges the benefit to outweigh the potential risks. Official guidance includes advice that women of child-bearing potential should use adequate methods of contraception during treatment.

Q: Can taking Adizem affect my mood?

A: Official safety documents list mood changes as a reported adverse reaction associated with the medication. This category may include changes such as depression or similar emotional shifts.

Q: Can Adizem cause issues with dental work or surgery?

A: Yes, official guidance states that the anesthetist or surgical team must be informed of ongoing diltiazem treatment prior to general anesthesia. This is necessary because anesthetics may potentiate (strengthen) the medication's effects on the heart.

How to Store and Dispose of Adizem

Adizem (diltiazem hydrochloride) must be stored under specific conditions to maintain its stability, as required by regulatory labeling.

Storage Requirements

The required storage environment is Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The temperature must not exceed 25 C. Storage should avoid excessive humidity, and the product must be kept in a tight, light-resistant container. As a critical safety precaution, Adizem must be stored out of the sight and reach of children.

Disposal Instructions

Official labeling mandates that unused or expired Adizem must not be thrown away via wastewater or household waste. Disposal should be handled by consulting a pharmacist for the proper method.